Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Cited by (967)

Items 301–400 of 967

1. Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
   Lucia Gelao, Carmen Criscitiello, Angela Espósito, Aron Goldhirsch, Giuseppe Curigliano · 2014 · Toxins
2. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
   Katherine E. Lewis, Mark Selby, Gregg R. Masters, Jose Valle, Gennaro Dito, Wendy Curtis, Richard García, Kathy A. Mink, Kimberly S. Waggie, Matthew S. Holdren et al. · 2017 · OncoImmunology
3. Prostate Cancer Immunotherapy
   Kenneth F. May, James L. Gulley, Charles G. Drake, Glenn Dranoff, Philip W. Kantoff · 2011 · Clinical Cancer Research
4. Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
   Ioana Plesca, Antje Tunger, Luise Müller, Rebekka Wehner, Xixi Lai, Marc‐Oliver Grimm, Sergio Rutella, Michael Philipp Bachmann, Marc Schmitz · 2020 · Frontiers in Immunology
5. Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
   Alfie T. Baker, Mohammed H. Abuwarwar, Lylarath Poly, Simon Wilkins, Anne L. Fletcher · 2021 · The Journal of Immunology
6. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
   Arsen Osipov, Adrian Gerard Murphy, Lei Zheng · 2019 · Advances in cancer research
7. TLR2-Dependent Induction of IL-10 and Foxp3+CD25+CD4+ Regulatory T Cells Prevents Effective Anti-Tumor Immunity Induced by Pam2 Lipopeptides In Vivo
   Sayuri Yamazaki, Kohei Okada, Akira Maruyama, Misako Matsumoto, Hideo Yagita∥, Tsukasa Seya · 2011 · PLoS ONE
8. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
   Wang, Manni, Liu, Yu, Cheng, Yuan, Wei, Yuquan, Wei, Xiawei · 2019 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
9. Checkpoint Inhibition in Myeloma: Opportunities and Challenges
   Federica Costa, Rituparna Das, Jithendra Kini Bailur, Kavita M. Dhodapkar, Madhav V. Dhodapkar · 2018 · Frontiers in Immunology
10. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
    Vincent Lavoué, Aurélie Thedrez, Jean Lévêque, Fabrice Foucher, Sébastien Henno, Vincent Jauffret, Marc‐Antoine Belaud‐Rotureau, Véronique Catros, Florian Cabillic · 2013 · Journal of Translational Medicine
11. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view
    Humera Memon, Bhoomika M. Patel · 2019 · Life Sciences
12. The perspective of immunotherapy
    Christian U. Blank · 2014 · Current Opinion in Oncology
13. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
    Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Satoshi Fukushima, Hiroshi Uchi, Naotaka Shibagaki, Arata Tsutsumida, Shusuke Yoshikawa, Ryuhei Okuyama, Yoshihiko Ito et al. · 2015 · Cancer Chemotherapy and Pharmacology
14. Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer: An Update
    Bing Xia, Roy S. Herbst · 2016 · Immunotherapy
15. Recent advances and future of immunotherapy for glioblastoma
    Neha Kamran, Anda‐Alexandra Calinescu, Marianela Candolfi, Mayuri Chandran, Yohei Mineharu, Antonela Sofía Asad, Carl Johannes Koschmann, Felipe Javier Núñez, Pedro Ricardo Lowenstein, Maria Graciela Castro · 2016 · Expert Opinion on Biological Therapy
16. Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
    Francesca De Felice, Cláudia Marchetti, Innocenza Palaia, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici · 2015 · Journal of Immunology Research
17. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
    Dharmesh Gopalakrishnan, Vadim S. Koshkin, Moshe Chaim Ornstein, Athanasios Papatsoris, Petros D. Grivas · 2018 · Therapeutics and Clinical Risk Management
18. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy
    Hamid Reza Mirzaei, Hossein Pourghadamyari, Majid Rahmati, Abbas Mohammadi, Javid Sadri Nahand, Abbas Rezaei, Hamed Mirzaei, Jamshid Hadjati · 2018 · Cancer Letters
19. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
    Margaret Ottaviano, Sabino De Placido, Paolo A. Ascierto · 2019 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
20. Targeting B7‐1 in immunotherapy
    Rui Chen, Aravindhan Ganesan, Isobel Okoye, Elena I Arutyunova, Shokrollah Elahi, M. Joanne Lemieux, Khaled Barakat · 2019 · Medicinal Research Reviews
21. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints
    Kristian Michael Hargadon · 2020 · Clinical and Translational Medicine
22. Regulatory T cells turn pathogenic
    Jitao Guo, Xuyu Zhou · 2015 · Cellular and Molecular Immunology
23. Mechanism of T cell exhaustion in a chronic environment
    Hyun-Tak Jin, Yun Hee Jeong, Hyo-Jin Park, Sang‐Jun Ha · 2011 · BMB Reports
24. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
    David Berman, Alan J. Korman, Ronald Peck, David Feltquate, Nils Lönberg, Renzo M. Canetta · 2014 · Pharmacology & Therapeutics
25. Recent advances in understanding antitumor immunity
    Rodrigo Ramella Munhoz, Michael Andrew Postow · 2016 · F1000Research
26. Dendritic cell immunotherapy
    Rachel Lubong Sabado, Nina Bhardwaj · 2013 · Annals of the New York Academy of Sciences
27. Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
    Simon Ville, Nicolas Poirier, Gilles Blancho, Bernard Vanhove · 2015 · Frontiers in Immunology
28. Unmasking the immune recognition of prostate cancer with CTLA4 blockade
    Serena S. Kwek, Edward Cha, Lawrence H. Fong · 2012 · Nature reviews. Cancer
29. Experimental animal modeling for immuno-oncology
    Qi‐Xiang Li, Gerold Feuer, Xuesong Ouyang, Xiaoyu An · 2017 · Pharmacology & Therapeutics
30. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
    A. Doran Bostwick, April K.S. Salama, Brent Allen Hanks · 2015 · Journal for ImmunoTherapy of Cancer
31. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment
    Fa-Peng Zhang, Yipei Huang, Weixin Luo, Wanyu Deng, Chaoqun Liu, Lei‐Bo Xu, Chao Liu · 2020 · World Journal of Gastroenterology
32. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
    Elena Goleva, Taras A. Lyubchenko, Lukas Kraehenbuehl, Mario E. Lacouture, Donald Y.M. Leung, Jeffrey A. Kern · 2021 · Annals of Allergy Asthma & Immunology
33. SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma
    Patricia Balsas, Luis Carlos Veloza, Guillem Clot, Marta Sureda-Gómez, Marta-Leonor Rodríguez, Christos Masaoutis, Gerard Frigola, Alba Navarro, Sı́lvia Beà, Ferran Nadeu et al. · 2021 · Blood
34. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
    Julie E. Bauman, Robert Louis Ferris · 2013 · Cancer
35. Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study
    Paola Queirolo, Anna Morabito, Stefania Laurent, Sonia Lastraioli, Patrizia Piccioli, Paolo A. Ascierto, Giusy Gentilcore, Martina Serra, Antonella Marasco, Elena Tornari et al. · 2013 · Cancer Investigation
36. CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells
    Jiehua Zhou, Asad Bashey, Ruikun Zhong, Sue Corringham, Karen S. Messer, Minya Pu, Wenxue Ma, Theresa Chut, Robert J. Soiffer, Rachel Mitrovich et al. · 2010 · Transplantation and Cellular Therapy
37. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
    Jia Li Low, Robert John Walsh, Yvonne L.E. Ang, Gloria Hui Jia Chan, Ross Andrew Soo · 2019 · Therapeutic Advances in Medical Oncology
38. CCL22 Signaling in the Tumor Environment
    Natascha Röhrle, Maximilian M. L. Knott, David Anz · 2020 · Advances in experimental medicine and biology
39. Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects
    Mungyo Jung, Mikyung Kang, Byung‐Seok Kim, Jihye Hong, Cheesue Kim, Choong‐Hyun Koh, Garam Choi, Yeonseok Chung, Byung‐Soo Kim · 2021 · Advanced Materials
40. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients
    Maria Napolitano, Crescenzo D’Alterio, Eleonora Cardone, Anna Maria Trotta, Biagio Pecori, Daniela Rega, Ugo Pace, Dario Scala, Giosuè Scognamiglio, Fabiana Tatangelo et al. · 2015 · Oncotarget
41. Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function
    Louisa E. Jeffery, Omar S. Qureshi, David H. Gardner, Tie Zheng Hou, Zoe Briggs, Blagoje Soskic, Jennifer Baker, Karim Raza, David Michael Sansom · 2015 · PLoS ONE
42. Cancer testis antigen and immunotherapy
    Deepa Kolaseri Krishnadas, Bai, Lucas · 2013 · ImmunoTargets and Therapy
43. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy
    Cole Friedes, Turja Chakrabarti, Sarah Olson, Laura M. Prichett, Julie Renee Brahmer, Patrick M. Forde, Khinh Ranh Voong, Kristen Ashley Marrone, Vincent K. L. Lam, Christine L. Hann et al. · 2021 · Lung Cancer
44. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
    Sorensen, Maria R., Holst, Peter J., Steffensen, Maria A., Christensen, Jan P., Thomsen, Allan R. · 2010 · Vaccine
45. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia
    Damien Saulep-Easton, Fabien B. Vincent, Melanie Le Page, Andrew H. Wei, Stephen B. Ting, Carlo Maria Croce, Constantine Si Lun Tam, Fabienne Mackay · 2014 · Leukemia
46. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
    Ingrid Teige, Linda Mårtensson, Björn Frendéus · 2019 · Frontiers in Immunology
47. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies
    Brianna M. Lax, Joseph R. Palmeri, Emi A. Lutz, Allison M. Sheen, Jordan A. Stinson, Lauren Duhamel, Luciano Santollani, Alan Kennedy, Adrienne M. Rothschilds, Stefani Spranger et al. · 2023 · Proceedings of the National Academy of Sciences
48. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
    Fade Aziz Mahmoud, Bradley D. Shields, Issam Makhoul, Nathan L. Avaritt, Henry K. Wong, Laura Fulper Hutchins, Sara C. Shalin, Alan J. Tackett · 2017 · Cancer Biology & Therapy
49. Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application
    Surface Oncology, 50 Hampshire Street, 8th Floor, Cambridge, MA 02139, USA, Matthew P. Rausch, Karen Taraszka Hastings · 2017 · Codon Publications eBooks
50. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells
    K. Jung, Jeong-Ah Kim, Ye-Jin Kim, Hyun Woo Lee, Chul-Ho Kim, S. Haam, Yong-Sung Kim · 2019 · Cancer immunology research
51. Immunotherapeutic Advancements for Glioblastoma
    Leonel Ampie, Eric C. Woolf, Christopher Dardis · 2015 · Frontiers in Oncology
52. Dendritic Cells
    Karolina Palucka, Hideki Ueno, Lee K. Roberts, Joseph W. Fay, Jacques Banchereau · 2010 · The Cancer Journal
53. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
    Yael S. Barach, Jun Sik Lee, Xingxing Zang · 2010 · Trends in Molecular Medicine
54. T-cell programming in pancreatic adenocarcinoma: a review
    Yongwoo David Seo, Venu Gopal Pillarisetty · 2016 · Cancer Gene Therapy
55. TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis
    Michael P. Holt, George A. Punkosdy, Deborah Dacek Glass, Ethan M. Shevach · 2017 · The Journal of Immunology
56. Adjuvant Therapy for Melanoma
    Maiko WADA-OHNO, Takamichi Ito, Masutaka Furue · 2019 · Current Treatment Options in Oncology
57. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
    Roy, Dia, Gilmour, Cassandra, Patnaik, Sachin, Wang, Li Lily · 2023 · Frontiers in Immunology
58. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
    Chang Woo Kim, Hong Jae Chon, Chan Kim · 2021 · Cancers
59. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
    Naoya Yamazaki, Hisashi Uhara, Satoshi Fukushima, Hiroshi Uchi, Naotaka Shibagaki, Yoshio Kiyohara, Arata Tsutsumida, Kenjiro Namikawa, Ryuhei Okuyama, Y. Otsuka et al. · 2015 · Cancer Chemotherapy and Pharmacology
60. The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
    Delia Jane Nelson, Scott A. Fisher, Bruce W. S. Robinson · 2014 · Journal of Immunology Research
61. A New VISTA on combination therapy for negative checkpoint regulator blockade
    Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J. Noelle · 2016 · Journal for ImmunoTherapy of Cancer
62. Immunotherapy in Glioblastoma
    Jessica A. Wilcox, Rohan R. Ramakrishna, Rajiv Magge · 2018 · World Neurosurgery
63. Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
    Johan Park, Bjørn Steen Skålhegg · 2025 · Frontiers in Immunology
64. Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
    Florencia P. Madorsky Rowdo, Antonela Barón, Mariela Urrutia, José Mordoh · 2015 · Frontiers in Immunology
65. Exploiting NK Cell Surveillance Pathways for Cancer Therapy
    A. Barrow, M. Colonna · 2019 · Cancers
66. Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy
    Helaina C. Regen-Tuero, Robert C. Ward, William M. Sikov, Peter J. Littrup · 2021 · Radiology Imaging Cancer
67. The paradox of immune checkpoint inhibition re-activating tuberculosis
    Mohamed I. M. Ahmed, Liku B. Tezera, Paul T. Elkington, Alasdair J. Leslie · 2022 · European Respiratory Journal
68. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification
    Mingyao Huang, Quansong Ji, Huiyan Huang, Xiaoqian Wang, Lin Wang · 2025 · Gut Microbes
69. Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
    Sadek Malas, Micaela Harrasser, Katie E. Lacy, Sophia N. Karagiannis · 2014 · Oncology Reports
70. Tumor immune surveillance and ovarian cancer
    Lana Elias Kandalaft, Gregory T. Motz, Jaikumar Duraiswamy, George Coukos · 2011 · Cancer and Metastasis Reviews
71. Novel therapeutic targets in advanced urothelial carcinoma
    Mathieu Rouanne, Yohann Loriot, Thierry Lebrét, Jean‐Charles Soria · 2015 · Critical Reviews in Oncology/Hematology
72. Melanoma: tumor microenvironment and new treatments
    Mara Giavina Bianchi, Pedro Francisco Giavina-Bianchi Junior, Cyro Festa Neto · 2017 · Anais Brasileiros de Dermatologia
73. Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
    Shabnam Babaei, Manouchehr Fadaee, Hajar Abbasi‐Kenarsari, Dariush Shanehbandi, Tohid Kazemi · 2024 · Cell Communication and Signaling
74. Predictive biomarkers in precision medicine and drug development against lung cancer
    Bingliang Fang, Reza John Mehran, John Victor Heymach, Stephen G. Swisher · 2015 · 癌症：英文版
75. Functional Mechanisms of Treg in the Context of HIV Infection and the Janus Face of Immune Suppression
    Jacobo López‐Abente, Rafael Correa‐Rocha, Marjorie Pion · 2016 · Frontiers in Immunology
76. Targeting immune checkpoints in malignant glioma
    Xuhao Zhang, Shan Zhu, Tete Li, Yongjun Liu, Wei Chen, Jingtao Chen · 2016 · Oncotarget
77. Epithelial-Stromal Interactions in Pancreatic Cancer
    Yaqing Zhang, Howard C. Crawford, Marina Pasca di Magliano · 2018 · Annual Review of Physiology
78. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
    Xiao-Jun Guo, Jia‐Cheng Lu, Haiying Zeng, Rong Zhou, Qi‐Man Sun, Guo‐Huan Yang, Yan-Zi Pei, Xian‐Long Meng, Ying‐Hao Shen, Pengfei Zhang et al. · 2021 · Frontiers in Immunology
79. Immunotherapy for Gastroesophageal Cancer
    E. Goode, Elizabeth Catherine Smyth · 2016 · Journal of Clinical Medicine
80. CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
    Holger Lingel, Josef B. Wissing, Aditya Arra, Denny Schanze, Stefan Lienenklaus, Frank Klawonn, Mandy Pierau, Martin Zenker, Lothar Jänsch, Monika Christine Brunner-Weinzierl · 2017 · Cell Death and Differentiation
81. Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
    Megan M Y Hong, Saman Maleki Vareki · 2022 · Cancers
82. Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery
    Marisa Market, Gayashan Tennakoon, Rebecca C. Auer · 2021 · International Journal of Molecular Sciences
83. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma
    A-Reum Kim, Seong Jin Choi, Junsik Park, Minsuk Kwon, Tamrin Chowdhury, Hyeon Jong Yu, Sojin Kim, Ho Kang, Kyung-Min Kim, Su-Hyung Park et al. · 2022 · OncoImmunology
84. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting
    Scott E. Kern, Chanjuan Shi, Ralph H. Hruban · 2010 · The Journal of Pathology
85. Checkpoint Blockade for the Treatment of Advanced Melanoma
    Margaret K. Callahan, Catherine Flaherty, Michael A. Postow · 2015 · Cancer treatment and research
86. New therapeutic strategies for malignant pleural mesothelioma
    Mara A. Bonelli, Claudia Fumarola, Silvia La Monica, Roberta R Alfieri · 2016 · Biochemical Pharmacology
87. Immune checkpoint inhibitors with radiotherapy and locoregional treatment
    Angela Espósito, Carmen Criscitiello, Giuseppe Curigliano · 2015 · Current Opinion in Oncology
88. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies
    Christopher Nishimura, Marc C. Pulanco, Wei Cui, Liming Lu, Xingxing Zang · 2020 · Trends in Molecular Medicine
89. BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
    Avery J. Salmon, Alexander S. Shavkunov, Qi Miao, Nicholas N. Jarjour, Sunita Keshari, Ekaterina Esaulova, Charmelle D. Williams, Jeffrey P. Ward, Anna M. Highsmith, Josue Estiven Pineda et al. · 2022 · Cancer Immunology Research
90. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
    Jianda D. Yuan, David B. Page, Geoffrey Yuyat Ku, Yanyun Li, Zhenyu Mu, Charlotte Eielson Ariyan, Humilidad F. Gallardo, Ruth-Ann Roman, Agnes I. Heine, Stephanie Lucia Terzulli et al. · 2010 · PubMed Central
91. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice
    Jon Ulf Hansen, Thomas Lindenstrøm, Julie Lindberg-Levin, Claus Aagaard, Peter Lawætz Andersen, Else Marie Agger · 2011 · Cancer Immunology Immunotherapy
92. Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy
    Eric K. Ring, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman · 2016 · Clinical Cancer Research
93. Tumor resident regulatory T cells
    Ariella Glasner, George Plitas · 2021 · Seminars in Immunology
94. Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
    Zeng Zhang, Xin Tan, Zengxin Jiang, Hao Wang, Hengfeng Yuan · 2022 · Frontiers in Pharmacology
95. Novel Systemic Therapies for Advanced Gastric Cancer
    Hong Jun Kim, Sang Cheul Oh · 2018 · Journal of the Korean Gastric Cancer Association
96. Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4
    Sergio A. Quezada, Karl S. Peggs · 2018 · Clinical Cancer Research
97. Noninvasive Imaging of Cancer Immunotherapy
    Omar Abousaway, Taha Rakhshandehroo, Annick D. Van den Abbeele, Moritz F. Kircher, Mohammad Rashidian · 2020 · Nanotheranostics
98. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
    Tao Ouyang, Xuefeng Kan, Chuansheng Zheng · 2022 · Frontiers in Oncology
99. Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
    Qingfei Wang, Shau-Hsuan Li, Hai Wang, Yi Qun Xiao, Özgür Şahin, Samuel W. Brady, Ping Li, Hailiang Ge, Elizabeth M. Jaffee, William J. Muller et al. · 2012 · Cancer Research
100. Cancer Immunotherapy: Whence and Whither
     Peter J. Stambrook, John F. Maher, Farzin Farzaneh · 2017 · Molecular Cancer Research